Cystatin c and Beta 2 Microglobulin in Thalassemic Children.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03881917|
Recruitment Status : Unknown
Verified March 2019 by Mohamed Naguib Khairy, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : March 20, 2019
Last Update Posted : March 20, 2019
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Blood Disease||Diagnostic Test: Cystatin c and beta 2 microglobulin kits|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Cystatin C and Beta 2 Microglobulin as Biochemical Markers for Early Detection of Renal Impairment in Children With Beta Thalassemia|
|Estimated Study Start Date :||November 1, 2019|
|Estimated Primary Completion Date :||November 1, 2020|
|Estimated Study Completion Date :||March 1, 2021|
- Diagnostic Test: Cystatin c and beta 2 microglobulin kits
Kits for measurement concentration
- mean difference of cystatin c and beta 2 microglobulin concentrations with normal range [ Time Frame: baseline ]Analysis of the results to differentiate the affected from non affected patients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||1 Year to 18 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
|Sampling Method:||Non-Probability Sample|
- Children with beta thalassemia from the age of 1 year to 18 years.
- Children who have other hematological or chronic disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03881917
|Contact: Mohamed Naguib Khairy, M.B.B.Chemail@example.com|
|Responsible Party:||Mohamed Naguib Khairy, Principle Investigator, Assiut University|
|Other Study ID Numbers:||
Renal markers in thalassemia.
|First Posted:||March 20, 2019 Key Record Dates|
|Last Update Posted:||March 20, 2019|
|Last Verified:||March 2019|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Cysteine Proteinase Inhibitors
Molecular Mechanisms of Pharmacological Action